Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
218 hedge funds and large institutions have $4.57B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2019 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 80 increasing their positions, 46 reducing their positions, and 15 closing their positions.
393% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 15
304% more call options, than puts
Call options by funds: $157M | Put options by funds: $38.8M
240% more funds holding in top 10
Funds holding in top 10: 5 → 17 (+12)
212% more capital invested
Capital invested by funds: $1.46B → $4.57B (+$3.1B)
74% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 46
33% more funds holding
Funds holding: 164 → 218 (+54)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$343M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$65.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.2M |
| 4 |
BlackRock
New York
|
+$52.7M |
| 5 |
DFO
Duquesne Family Office
New York
|
+$46.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$36M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$33M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$30.9M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$19.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
226
Walleye Trading
New York
| – | -$656K | -3,594 | Closed |
|
|
TI
227
Trexquant Investment
Stamford,
Connecticut
| – | -$262K | -3,267 | Closed |
|
228
Parallax Volatility Advisers
San Francisco,
California
| – | -$201K | -2,499 | Closed |
|
|
TRCT
229
Tower Research Capital (TRC)
New York
| – | -$44K | -545 | Closed |
|
|
LC
230
Lindbrook Capital
Calabasas,
California
| – | -$32K | -400 | Closed |
|
|
CCA
231
Catalyst Capital Advisors
Huntington,
New York
| – | -$7K | -85 | Closed |
|
|
NFG
232
Next Financial Group
Houston,
Texas
| – | -$1K | -12 | Closed |
|
|
AG
233
Advisor Group
Phoenix,
Arizona
| – | +$365 | +2 | New |
|
RETA Hedge Fund Activity: Q4 2019 in Review
218 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q4 2019, worth a combined $4.57B — up 212% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new RETA positions and 15 closed out — a net gain of 59 holders — while 80 added to existing stakes and 46 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $343M. The largest seller was Driehaus Capital Management, cutting an estimated $36M.
- 218 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q4 2019, up from 164 in Q3 2019.
- Funds reported $4.57B of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q4 2019, up 212% quarter-over-quarter.
- 74 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q4 2019 and 15 closed out, a net change of +59 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q4 2019 was Wellington Management Group, an estimated $343M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q4 2019 was Driehaus Capital Management, an estimated $36M sold.
Based on aggregated 13F filings for Q4 2019.